Clinical Trials
25 trialsTesting the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
National Cancer Institute (NCI)
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
SAMCO
Federation Francophone de Cancerologie Digestive
Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer
Ohio State University Comprehensive Cancer Center
Resection Observatory
Sanofi
FOLFA
Federation Francophone de Cancerologie Digestive
ELDERLY
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
AFEMA
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Efficacy and Safety of Aflibercept in Combination With FOLFIRI Chemotherapy as 1st Line Treatment for Patients With Metastatic Colorectal Cancer
Federation Francophone de Cancerologie Digestive
Plasma Biomarker for Aflibercept in Advanced Colorectal Cancer
Yonsei University
ARBITRATION
National Cancer Institute, Naples
C261
Brown University
PERMAD
University of Ulm
MINOAS
Hellenic Oncology Research Group
X-TRAP
Duke University
MOMENTUM1
Jules Bordet Institute
AMALTHEA
Hellenic Cooperative Oncology Group
AUSCOR
Barts & The London NHS Trust
A Phase II Study of Ziv-aflibercept in Combination With Capecitabine/Oxaliplatin (XELOX) Chemotherapy in the Front-Line Treatment of Patients With Metastatic Colorectal Cancer
University of Pittsburgh
BOS3
European Organisation for Research and Treatment of Cancer - EORTC
Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer
CR-CSSS Champlain-Charles-Le Moyne
AFFIRM
Sanofi
Safety and Effectiveness Study of Chemotherapy and Ziv-aflibercept to Treat Metastatic Colorectal Cancer
NSABP Foundation Inc
Study of Intravenous Aflibercept in Combination With FOLFIRI in Japanese Patients With Metastatic Colorectal Cancer
Sanofi
VELOUR
Sanofi